Welcome from our chairperson

Welcome to HaemOnc 2026.

The South African Clinical Haematology Society is proud to welcome you to HaemOnc 2026, taking place in Cape Town under the theme “Beyond Boundaries: From Progress to Access.”

This year’s meeting focuses on a defining challenge in haematology and oncology: moving beyond discovery to ensure that innovation reaches patients in meaningful and sustainable ways. While scientific progress continues to accelerate, access to diagnostics and treatment remains a pressing issue across many healthcare systems.

HaemOnc 2026 will bring together clinicians, laboratory specialists, researchers, industry partners, and policymakers to explore practical pathways from innovation to implementation. Through integrated clinical and diagnostic perspectives, local and international expertise, and robust academic engagement, the meeting aims to drive collaboration and real-world solutions.

We look forward to welcoming you to a meeting that is purposeful, forward-thinking, and firmly focused on improving patient care.

Vernon Louw
President: South African Clinical Haematology Society (SACHaS)

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

b

Registration

Early bird: 01 Mar – 30 Jun 2026
Late: 01 Jul  – 05 Sep 2026

l

Abstracts

Opening date: 01 Mar 2026
Closing date: 24 August 2026

Trade

Join us to contribute to and take part in another memorable HaemOnc experience.

About AstraZeneca

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes. We believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Activity ID: ZA-6886; Expiry date: 30 June 2028

https://www.astrazeneca.com/country-sites/african-cluster.html

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built on our heritage in diabetes. Through scientific innovation, expanded access to medicines, and partnerships across healthcare and technology, we help bring meaningful solutions to patients worldwide. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter, Instagram and YouTube.

Loading...